Regeneron Pharmaceuticals (NASDAQ:REGN) Cut to Buy at Wall Street Zen

Wall Street Zen cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a report released on Saturday,Wall Street Zen reports.

A number of other brokerages also recently commented on REGN. Leerink Partners lifted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research report on Monday, August 17th. Truist Financial raised their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Royal Bank Of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $793.74 on Friday. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $859.34. The business’s 50-day moving average price is $757.80 and its two-hundred day moving average price is $720.27. The firm has a market cap of $81.72 billion, a PE ratio of 19.62, a P/E/G ratio of 1.53 and a beta of 0.20. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Buying and Selling

In related news, Director Arthur Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 4,146 shares of company stock worth $3,432,488. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Tidal Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 10.7% during the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock worth $27,371,000 after purchasing an additional 4,244 shares during the last quarter. National Pension Service increased its stake in Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock valued at $236,830,000 after buying an additional 8,264 shares during the last quarter. Krensavage Asset Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 50.0% during the 2nd quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company’s stock worth $3,741,000 after buying an additional 2,000 shares in the last quarter. Engineers Gate Manager LP lifted its position in shares of Regeneron Pharmaceuticals by 4,309.4% during the 2nd quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company’s stock worth $9,926,000 after buying an additional 15,557 shares in the last quarter. Finally, Cidel Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 7.8% in the 2nd quarter. Cidel Asset Management Inc. now owns 775 shares of the biopharmaceutical company’s stock worth $483,000 after buying an additional 56 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.